News

NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, has been approved for sale in the UK under The Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations…

Agreement will initially cover the UK and France with potential to expand to other European…

The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China…

Rising to the challenge: diagnosing, treating and managing respiratory infections using rapid PCR testing at the Point of Care. NEWCASTLE UPON TYNE, UK, 5 July 2022. QuantuMDx Group Limited (“QuantuMDx”) will be offering insights and advice on tackling respiratory infections…